Health Anxiety and Its Relationship to Thyroid-Hormone-Suppression Therapy in Patients with Differentiated Thyroid Cancer

被引:3
|
作者
Zoltek, Maximilian [1 ]
Andersson, Therese M-L [2 ]
Axelsson, Erland [3 ,4 ,5 ,6 ]
Hedman, Christel [1 ,7 ,8 ]
Lundgren, Catharina Ihre [1 ,9 ]
机构
[1] Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17176 Stockholm, Sweden
[3] Karolinska Inst, Dept Neurobiol Care Sci & Soc, S-14152 Huddinge, Sweden
[4] Karolinska Inst, Dept Clin Neurosci, S-17165 Solna, Sweden
[5] Reg Stockholm, Liljeholmen Primary Hlth Care Ctr, S-11763 Stockholm, Sweden
[6] Reg Stockholm, Acad Primary Hlth Care Ctr, S-11365 Stockholm, Sweden
[7] Stockholms Sjukhem Fdn, Res & Dev Dept, Mariebergsgatan 22, S-11219 Stockholm, Sweden
[8] Lund Univ, Dept Clin Sci Lund, Div Palliat Care, Scheelevagen 2, S-22381 Lund, Sweden
[9] Karolinska Univ Hosp, Dept Breast Endocrine Tumours & Sarcoma, S-17176 Stockholm, Sweden
关键词
health anxiety; differentiated thyroid cancer; thyroid-stimulating hormone; QUALITY-OF-LIFE; THYROTROPIN SUPPRESSION; BREAST-CANCER; CARCINOMA; PREVALENCE; RECURRENCE; DISABILITY; INVENTORY;
D O I
10.3390/cancers14102349
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Differentiated thyroid cancer (DTC) has a good prognosis; however, patients often need lifelong follow up and face potentially chronic psychiatric problems, such as health anxiety. We investigated the relationship between health anxiety and TSH-suppression treatment, which many patients receive lifelong. The health anxiety was assessed by using the 14-item Short Health Anxiety Inventory (SHAI-14), which is scored 0-42; higher values indicate more health anxiety. Out of 146 patients with DTC, 24 (16%) had clinically significant health anxiety. Patients with TSH levels of 0.1-0.5 (mE/L) scored, on average, 3.28 points more (p-value 0.01) on the SHAI-14 compared to patients with TSH levels > 0.5. We found that health anxiety appears to be slightly more common among DTC patients compared to the general population, but this was not clearly connected to the TSH-suppression treatment. Differentiated thyroid cancer (DTC) has a good prognosis; however, patients often need lifelong follow up, and they face potential side effects. The aim of this study was to investigate health anxiety among DTC patients and its relationship to TSH suppression. In 2020, patients from a previous cohort who were from Stockholm completed the 14-item Short Health Anxiety Inventory (SHAI-14; 0-42; 18 being the threshold for clinical significance) and a study-specific questionnaire. Clinical information was also retrieved from medical records. Linear regression was used to investigate the relationship between the TSH levels and the SHAI-14, while adjusting for potential confounders. In total, 146 (73%) patients were included. A total of 24 respondents (16%) scored 18 or more on the SHAI-14, and the mean score was 11.3. Patients with TSH levels of 0.1-0.5 (mE/L) scored, on average, 3.28 points more (p-value 0.01) on the SHAI-14 compared to patients with TSH levels > 0.5. There was no statistically significant difference between patients with TSH levels < 0.1 and TSH levels > 0.5. Thus, we found no linear relationship between the TSH values and health anxiety. Clinically significant levels of health anxiety are slightly higher than those in the general population, but do not appear to be a major psychiatric comorbidity among patients with DTC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Thyroid hormone therapy in differentiated thyroid cancer
    Giorgio Grani
    Valeria Ramundo
    Antonella Verrienti
    Marialuisa Sponziello
    Cosimo Durante
    [J]. Endocrine, 2019, 66 : 43 - 50
  • [2] Thyroid hormone therapy in differentiated thyroid cancer
    Grani, Giorgio
    Ramundo, Valeria
    Verrienti, Antonella
    Sponziello, Marialuisa
    Durante, Cosimo
    [J]. ENDOCRINE, 2019, 66 (01) : 43 - 50
  • [3] Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
    Benjamin J. Gigliotti
    Sina Jasim
    [J]. Endocrine, 2024, 83 : 251 - 258
  • [4] Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
    Gigliotti, Benjamin J.
    Jasim, Sina
    [J]. ENDOCRINE, 2024, 83 (02) : 251 - 258
  • [5] Differentiated Thyroid Cancer in Two Patients with Resistance to Thyroid Hormone
    Paragliola, Rosa Maria
    Lovicu, Rosa Maria
    Locantore, Pietro
    Senes, Paola
    Concolino, Paola
    Capoluongo, Ettore
    Pontecorvi, Alfredo
    Corsello, Salvatore Maria
    [J]. THYROID, 2011, 21 (07) : 793 - 797
  • [6] Thyroid hormone and its metabolites in relation to quality of life in patients treated for differentiated thyroid cancer
    Massolt, E. T.
    van der Windt, M.
    Korevaar, T. I. M.
    Kam, B. L. R.
    Burger, J. W.
    Franssen, G. J. H.
    Lehmphul, I.
    Koehrle, J.
    Visser, W. E.
    Peeters, R. P.
    [J]. CLINICAL ENDOCRINOLOGY, 2016, 85 (05) : 781 - 788
  • [7] Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer
    Iniguez-Ariza, Nicole M.
    Stan, Marius N.
    Bible, Keith C.
    [J]. ENDOCRINE, 2018, 59 (01) : 228 - 229
  • [8] Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer
    Nicole M. Iñiguez-Ariza
    Marius N. Stan
    Keith C. Bible
    [J]. Endocrine, 2018, 59 : 228 - 229
  • [9] Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma
    Wang, Ruihua
    Yang, Liu
    Jin, Shui
    Han, Xingmin
    Liu, Baoping
    [J]. CANCER CELL INTERNATIONAL, 2018, 18
  • [10] Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma
    Ruihua Wang
    Liu Yang
    Shui Jin
    Xingmin Han
    Baoping Liu
    [J]. Cancer Cell International, 18